Is There a Need for Another Inhalative β₂-Agonist besides Formoterol in Patients with Asthma?

Publisher： Karger

E-ISSN： 1423-0356|68|4|432-437

ISSN： 0025-7931

Source： Respiration, Vol.68, Iss.4, 2001-07, pp. : 432-437

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhalation devices for long-acting β₂-agonists: efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD

By Molimard Mathieu Till Denise Stenglein Stephan Singh Dilraj Krummen Markus

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2405-2413

Informa Healthcare

Access to resources Recommend Favorite

Inhaled Corticosteroid/Long-Acting β₂-Agonist Combination Therapy for Asthma: Attitudes of Specialists in Europe

International Archives of Allergy and Immunology, Vol. 157, Iss. 3, 2011-11 ,pp. : 303-310

Karger

Access to resources Recommend Favorite

Comparative Effects of Desloratadine versus Montelukast on Asthma Symptoms and Use of β₂-Agonists in Patients with Seasonal Allergic Rhinitis and Asthma

International Archives of Allergy and Immunology, Vol. 130, Iss. 4, 2003-05 ,pp. : 307-313

Karger

Access to resources Recommend Favorite

Do we need another SGLT2 inhibitor?

PRACTICAL DIABETES (INCORPORATING CARDIABETES), Vol. 32, Iss. 2, 2015-03 ,pp. : 47-48a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma

By Buhl R Vogelmeier C

Current Medical Research and Opinion, Vol. 23, Iss. 8, 2007-08 ,pp. : 1867-1878

Informa Healthcare

Access to resources Recommend Favorite